RESEARCH ARTICLE

REVISED All thresholds of maternal hyperglycaemia from the WHO 2013 criteria for gestational diabetes identify women with a higher genetic risk for type 2 diabetes [version 2; peer review: 3 approved with reservations]

Alice E. Hughes ^{1,2}, M. Geoffrey Hayes³, Aoife M. Egan⁴, Kashyap A. Patel ^{1,2}, Denise M. Scholtens³, Lynn P. Lowe³, William L. Lowe Jr ³, Fidelma P. Dunne⁵, Andrew T. Hattersley^{1,2,6}, Rachel M. Freathy ¹

¹Institute of Biomedical and Clinical Science, University of Exeter, Exeter, UK

²Royal Devon and Exeter Hospitals NHS Foundation Trust, Exeter, UK

³Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

⁴Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic School of Medicine, Rochester, MN, USA

⁵Galway Diabetes Research Centre and Saelta Hospital Group, National University of Ireland, Galway, Galway, Ireland

⁶National Institute for Health Research Exeter Clinical Research Facility, Exeter, UK

v2 First published: 22 Jul 2020, 5:175
<https://doi.org/10.12688/wellcomeopenres.16097.1>
 Second version: 03 Nov 2020, 5:175
<https://doi.org/10.12688/wellcomeopenres.16097.2>
 Latest published: 23 Mar 2021, 5:175
<https://doi.org/10.12688/wellcomeopenres.16097.3>

Abstract

Background: Using genetic scores for fasting plasma glucose (FPG GS) and type 2 diabetes (T2D GS), we investigated whether the fasting, 1-hour and 2-hour glucose thresholds from the WHO 2013 criteria for gestational diabetes (GDM) have different implications for genetic susceptibility to raised fasting glucose and type 2 diabetes in women from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) and Atlantic Diabetes in Pregnancy (DIP) studies.

Methods: Cases were divided into three subgroups: (i) FPG ≥ 5.1 mmol/L only, n=222; (ii) 1-hour glucose post 75 g oral glucose load ≥ 10 mmol/L only, n=154 (iii) 2-hour glucose ≥ 8.5 mmol/L only, n=73; and (iv) both FPG ≥ 5.1 mmol/L and either of a 1-hour glucose ≥ 10 mmol/L or 2-hour glucose ≥ 8.5 mmol/L, n=172. We compared the FPG and T2D GS of these groups with controls (n=3,091) in HAPO and DIP separately.

Results: In HAPO and DIP, the mean FPG GS in women with a FPG ≥ 5.1 mmol/L, either on its own or with 1-hour glucose ≥ 10 mmol/L or 2-hour glucose ≥ 8.5 mmol/L, was higher than controls (all $P < 0.01$). Mean T2D GS in women with a raised FPG alone or with either a raised 1-hour or 2-hour glucose was higher than controls (all $P < 0.05$). GDM defined by 1-hour or 2-hour hyperglycaemia only was also associated with a higher T2D GS than controls (all $P < 0.05$).

Open Peer Review

Approval Status

	1	2	3
version 3			
(revision)			
23 Mar 2021	view	view	
version 2			
(revision)			
03 Nov 2020	view	view	view
version 1			
22 Jul 2020			
	view		

1. **Vivian K. Kawai**, Vanderbilt University School of Medicine, Nashville, USA
2. **Nael Shaat** , Skåne University Hospital, Malmö, Sweden
Lund University, Malmö, Sweden
3. **Amel Lamri** , McMaster University,

Conclusions: The different diagnostic categories that are part of the WHO 2013 criteria for GDM identify women with a genetic predisposition to type 2 diabetes as well as a risk for adverse pregnancy outcomes.

Keywords

Gestational diabetes, genetic scores, fasting plasma glucose, type 2 diabetes

Hamilton, Canada

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Rachel M. Freathy (r.freathy@exeter.ac.uk)

Author roles: **Hughes AE:** Formal Analysis, Investigation, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Hayes MG:** Data Curation, Formal Analysis, Writing – Review & Editing; **Egan AM:** Data Curation, Writing – Review & Editing; **Patel KA:** Formal Analysis, Writing – Review & Editing; **Scholtens DM:** Data Curation, Formal Analysis, Writing – Review & Editing; **Lowe LP:** Data Curation, Writing – Review & Editing; **Lowe Jr WL:** Conceptualization, Data Curation, Methodology, Supervision, Writing – Review & Editing; **Dunne FP:** Conceptualization, Data Curation, Formal Analysis, Methodology, Supervision, Writing – Review & Editing; **Hattersley AT:** Conceptualization, Formal Analysis, Methodology, Supervision, Writing – Review & Editing; **Freathy RM:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by Wellcome [GW4 Clinical Academic Training PhD Fellowship to AEH; 110082, Postdoctoral Training Fellowship to KAP; 104150, a Wellcome and Royal Society Sir Henry Dale Fellowship to RMF; 088541, a Sir Henry Wellcome Postdoctoral Fellowship to RMF was used to fund genotyping of the SNPs in HAPO and DIP]. AEH was also funded by the National Institute of Health Research (NIHR). ATH is a Wellcome Trust Senior Investigator (098395) and NIHR senior investigator. HAPO was supported by grants from Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD-34242 and HD-32423), National Human Genome Research Institute (HG-004415), the National Institute of Diabetes and Digestive and Kidney Diseases (DK-DK097534) and the American Diabetes Association. DIP was supported by grants from the Ireland Health Research Board. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2020 Hughes AE *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Hughes AE, Hayes MG, Egan AM *et al.* **All thresholds of maternal hyperglycaemia from the WHO 2013 criteria for gestational diabetes identify women with a higher genetic risk for type 2 diabetes [version 2; peer review: 3 approved with reservations]** Wellcome Open Research 2020, 5:175 <https://doi.org/10.12688/wellcomeopenres.16097.2>

First published: 22 Jul 2020, 5:175 <https://doi.org/10.12688/wellcomeopenres.16097.1>

REVISED Amendments from Version 1

In response to Review 1 we have made changes to the text of Version 1. In the Introduction we have edited the last paragraph to explain the aim of the study. In the Methods (under the "Study characteristics" header) we clarify that women of European ancestry were defined as self-reported white ethnicity. Under the "Generating a genetic score for FPG and type 2 diabetes" header of the Methods we include a reference to the effect sizes used in Table 1 and Table 2. We updated the "Statistical analyses" section of the Methods to include reference to analyses in the DIP Study. This is accompanied by a second section of Table 4 (Table 4B) with the results of this analysis. To address comments about biological relevance, predictive ability of genetic scores for GDM and type 2 diabetes risk and implications of a raised genetic risk for type 2 diabetes for long-term follow-up we have updated the "Discussion and conclusions" section with additional information covering these areas.

Any further responses from the reviewers can be found at the end of the article

Introduction

Gestational diabetes mellitus (GDM) has been variably defined since criteria were first developed over 50 years ago¹. The World Health Organization (WHO) introduced diagnostic criteria for GDM in 1999, based on criteria for overt diabetes in the general population, with a fasting plasma glucose (FPG) ≥ 7.0 mmol/L or impaired glucose tolerance with a 2-hour glucose ≥ 7.8 mmol/L post 75 g oral glucose load as part of an oral glucose tolerance test (OGTT), measured between 24 and 28 weeks gestation². However, lesser degrees of maternal fasting hyperglycaemia have long been associated with a higher risk for adverse perinatal outcomes³, so a FPG ≥ 6.1 mmol/L (indicative of impaired fasting glycaemia in the non-pregnant population⁴) was also integrated into the WHO criteria.

The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study⁵ followed 23,316 women who underwent a 2-hour OGTT between 24 and 32 weeks gestation throughout pregnancy and found a continuous association between maternal glucose values and adverse perinatal outcomes, including birth weight $\geq 90^{\text{th}}$ centile (large for gestational age, LGA) and primary caesarean section. In 2010, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) determined cut-off values equivalent to 1.75 times the odds for adverse pregnancy outcomes at mean glucose values, resulting in diagnostic thresholds for FPG ≥ 5.1 mmol/L, 1-hour glucose ≥ 10 mmol/L and 2-hour glucose ≥ 8.5 mmol/L⁶.

WHO adopted the recommendations of IADPSG in 2013², which has resulted in a higher number of cases identified as GDM due to the lower FPG threshold (estimated up to 17.8% prevalence of GDM for IADPSG 2010 criteria⁶ vs 9.4% prevalence for WHO 1999 criteria⁷). Whilst these thresholds were chosen for their Obstetric risks, the HAPO Follow-Up Study found that women diagnosed by the newer criteria have a higher risk of developing disorders of glucose metabolism, including T2D, 10 years after the episode of GDM⁸. A proportion of this risk can be attributed to genetic predisposition, since genome wide

association study (GWAS) data from large, non-pregnant population-based studies have identified multiple loci associated with FPG⁹ and type 2 diabetes¹⁰ and some of these are shared with GDM^{11–16}. Specific to the WHO 2013 criteria, single nucleotide polymorphisms (SNPs) at the *GCK* and *TCF7L2* loci were shown to be associated with FPG and 2-hour glucose levels post-OGTT in women with GDM¹⁷. In addition, genetic risk scores for glycaemic traits, including FPG and type 2 diabetes, have been associated with a higher odds for GDM according to the WHO 2013 criteria¹⁸. However, it is not known whether the underlying genetic predisposition to fasting hyperglycaemia and type 2 diabetes varies depending on how the diagnosis of GDM is met.

The objective of this study was to investigate whether there is a difference in genetic risk for fasting hyperglycemia and type 2 diabetes according to the different diagnostic thresholds of glucose tolerance from the WHO 2013 criteria for GDM. To do this, we used a genetic score (GS) for FPG (FPG GS) or T2D (T2D GS) (consisting of previously-identified loci^{9,19})

Methods

Study population

Women of European ancestry (self-reported white ethnicity) with singleton pregnancies and without known pre-existing diabetes from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study⁵ ($n=2,628$) and Atlantic Diabetes in Pregnancy (DIP) study²⁰ ($n=1,084$) were included. The HAPO study was an observational, multi-centre study ($N=23,316$ participants from 15 centres) to which women were recruited during pregnancy if they were over 18 years of age⁵. The 2,665 European-ancestry participants included in the current study were those with genotype data available on selected SNPs (see below). The DIP study had a case-control design: approximately three genotyped control participants without GDM (defined initially as a maternal FPG < 5.6 mmol/L and/or 2-hour glucose post oral glucose load < 7.8 mmol/L) were available for every genotyped case participant included in our analyses.

Sample collection and clinical characteristics

The study methods used in HAPO and DIP have been described in detail previously^{5,7,20–22}. Maternal FPG in mmol/L was measured prior to a standard 2-hour OGTT with 75 g of glucose between 24 and 32 weeks in HAPO and 24 and 28 weeks in DIP. Information on maternal age, pre-pregnancy body mass index (BMI) and systolic blood pressure (SBP, in mmHg) was collected at the OGTT appointment. Clinical characteristics of participants in HAPO and DIP with and without GDM were different (women in DIP were older, had a higher BMI and higher SBP, all $P < 0.01$), hence clinical characteristics (where available) have been presented separately.

GDM diagnostic criteria subgroups

We used the WHO 2013 cut-offs (previously IADPSG 2010) to define fasting and 2-hour hyperglycaemia. Thus, in the current study, women diagnosed with GDM were divided into fasting hyperglycaemia only (FPG ≥ 5.1 mmol/L and 1-hour and 2-hour glucose post 75 g oral glucose load < 10 mmol/L and < 8.5 mmol/L, respectively, $n=222$), elevated 1-hour glucose only

(1-hour glucose ≥ 10 mmol/L, FPG < 5.1 mmol/L and 2-hour glucose < 8.5 mmol/L, $n=154$), elevated 2-hour glucose only (2-hour glucose ≥ 8.5 mmol/L, FPG < 5.1 mmol/L and 1-hour glucose < 10 mmol/L, $n=73$) and both (FPG ≥ 5.1 mmol/L and either a 1-hour glucose ≥ 10 mmol/L or 2-hour glucose ≥ 8.5 mmol/L, or both, $n=172$) subgroups [Figure 1](#). Women without GDM were defined as having FPG < 5.1 mmol/L, 1-hour glucose < 10 mmol/L and 2-hour glucose < 8.5 mmol/L ($n=3,091$). The distributions of the women in the different groups and in each of the study cohorts are shown in [Figure 1](#).

Genotyping

Genotyping of individual SNPs in DNA samples from both the DIP and HAPO studies was carried out at LGC Genomics (Hoddesdon, UK), using the PCR-based KASP™ genotyping assay. We first selected 41 SNPs that had been previously associated with type 2 diabetes, and 16 SNPs associated with fasting glucose in non-pregnant individuals, for genotyping in the DIP study. Overlap between the type 2 diabetes and FPG SNPs meant that seven FPG loci were also in the list of type 2 diabetes loci. The median genotyping call rate in the DIP samples was 0.992 (range 0.981–0.996), and there was $>99\%$ concordance between duplicate samples (8% of total genotyped samples were duplicates). We excluded one FPG SNP and one type 2 diabetes SNP that showed deviation from Hardy-Weinberg Equilibrium

(Bonferroni-corrected P value < 0.05). For details of included and excluded SNPs and their sources, see [Table 1](#) and [Table 2](#).

In the HAPO study, we selected SNPs from the same 16 FPG and 41 type 2 diabetes loci for genotyping in women of European ancestry with DNA available. The selection and genotyping of SNPs in the HAPO study was performed at different times from that in the DIP study. Owing to the differing availability of published GWAS results at these times, the genotyped SNPs differed between HAPO and DIP at 9 of the associated loci. The HAPO SNPs at the nine loci were generally well correlated with those genotyped in DIP ($r^2 > 0.7$, apart from at the *ADAMTS9* locus where $r^2 = 0.45$). The median genotyping call rate in the HAPO samples was 0.984 (range 0.955–0.991), and the mean concordance between duplicate samples was $>98.5\%$ (at least 1% of samples were duplicated). We excluded one SNP that showed deviation from Hardy-Weinberg Equilibrium in the HAPO study (Bonferroni-corrected P value < 0.05 ; see [Table 1](#) and [Table 2](#)). After exclusion of SNPs that showed deviation from Hardy-Weinberg equilibrium and one SNP from the type 2 diabetes score whose main effect was on BMI (*rs11642841* (*FTO* locus)²³, a total of 15 SNPs at FPG-associated loci and 38 SNPs at type 2 diabetes-associated loci were available in both studies for analysis.

Figure 1. Distribution of participants diagnosed with gestational diabetes (GDM) by different glucose categories in Hyperglycemia and Adverse Pregnancy Outcome Study (HAPO) and Atlantic Diabetes in Pregnancy Study (DIP). All glucose values are in mmol/L. The 1-hour and 2-hour glucose measures refer to the glucose level measured at 1 and 2 hours, respectively, following a 75 g oral glucose load as part of an oral glucose tolerance test. Women with a FPG ≥ 5.1 mmol/L and either a 1-hour glucose ≥ 10 mmol/L or 2-hour glucose ≥ 8.5 mmol/L, or both, were combined as one group for analyses.

Table 1. Fifteen SNPs associated with fasting plasma glucose (FPG) and used to construct the FPG genetic score.

Chr:Pos (hg19)	SNP (proxy) ^a	Locus	Alleles (Effect/Other)	Effect Allele Frequency ^b	Beta (mmol/L) ^c
1:214159256	rs340874	<i>PROX1</i>	C/T	0.57	0.013
2:27741237	rs780094	<i>GCKR</i>	C/T	0.62	0.029
2:169763148	rs560887	<i>G6PC2</i>	C/T	0.70	0.075
3:123065778	rs11708067 (rs2877716)	<i>ADCY5</i>	A/G	0.75	0.027
3:170717521	rs11920090	<i>SLC2A2</i>	T/A	0.88	0.020
7:15064309	rs2191349	<i>DGKB/TMEM195</i>	T/G	0.55	0.030
7:44235668	rs4607517 (rs1799884)	<i>GCK</i>	A/G	0.18	0.062
8:118184783	rs13266634	<i>SLC30A8</i>	C/T	0.69	0.027
9:4289050	rs7034200	<i>GLIS3</i>	A/C	0.48	0.018
10:114758349	rs7903146	<i>TCF7L2</i>	T/C	0.29	0.023
11:45873091	rs11605924	<i>CRY2</i>	A/C	0.48	0.015
11:47336320	rs7944584	<i>MADD</i>	A/T	0.72	0.021
11:61571478	rs174550	<i>FADS1</i>	T/C	0.65	0.017
11:92708710	rs10830963	<i>MTNR1B</i>	G/C	0.28	0.067
15:62433962	rs11071657	<i>C2CD4B</i>	A/G	0.62	0.008

SNP, single nucleotide polymorphism.

^aProxy SNPs were genotyped and analysed in the Hyperglycemia and Adverse Pregnancy Outcome Study (both $r^2 > 0.85$ in 340,000 British white unrelated samples from UK Biobank²⁴).

^bEffect allele frequency was calculated in 340,000 British white unrelated samples from the UK Biobank²⁴.

^cBeta values were aligned to the trait-raising allele on the + strand (Human Genome Assembly Reference hg19). Source of SNPs and beta values: Dupuis *et al.*, 2010⁹.

We excluded rs10885122 (*ADRA2A* locus) due to deviation from Hardy-Weinberg Equilibrium in the Atlantic Diabetes In Pregnancy Study (Bonferroni corrected $P < 0.05$).

Generating a genetic score for FPG and type 2 diabetes

Weighted genetic scores for FPG (FPG GS) and type 2 diabetes (T2D GS) were generated using the 15 SNPs and 38 SNPs, respectively. The GSs were calculated by taking the sum of the number of FPG-raising or type 2 diabetes risk alleles (0, 1 or 2) for each SNP, multiplied by its corresponding beta value (effect size, see Table 1 and Table 2) for association with FPG or type 2 diabetes, divided by the sum of all beta values and multiplied by the total number of SNPs analysed (see Figure 2 for formula). GS were generated for participants with complete data for all included SNPs only.

Statistical analyses

Analysis of clinical characteristics. Clinical characteristics were compared between participants with and without GDM in

HAPO and DIP using unpaired *t*-tests for normally distributed data and the Wilcoxon Rank-Sum test for non-normally distributed data. *P* values were corrected for 24 comparisons using the Bonferroni method.

Analysis of associations between FPG GS or T2D GS with glucose levels and GDM. Associations of the FPG GS or T2D GS with FPG, 1-hour and 2-hour glucose in women with and without GDM (cases and controls) were analysed using linear regression in HAPO (which was a representative sample of European participants from the whole study cohort) and DIP. *P* values were corrected for 24 comparisons using the Bonferroni method. Means for FPG GS and T2D GS in women with and without GDM were compared using unpaired *t*-tests in each study cohort separately, as the genetic scores were

Table 2. Thirty-eight SNPs associated with type 2 diabetes (T2D) risk and used to construct the T2D genetic score.

Chr:Pos (hg19)	SNP (proxy) ^a	Locus	Alleles (Effect/Other)	Effect Allele Frequency ^b	Beta ^c	Source in which SNP was originally identified
1:120526982	rs1493694	NOTCH2	T/C	0.11	0.110	Zeggini <i>et al.</i> , 2008 ²⁵
1:214163675	rs340835	PROX1	A/G	0.49	0.062	Dupuis <i>et al.</i> , 2010 ⁹
2:27741237	rs780094	GCKR	C/T	0.62	0.011	Dupuis <i>et al.</i> , 2010 ⁹
2:43732823	rs7578597	THADA	T/C	0.89	0.141	Zeggini <i>et al.</i> , 2008 ²⁵
2:60584819	rs243021	BCL11A	A/G	0.46	0.090	Voight <i>et al.</i> , 2010 ²⁶
2:227093745	rs2943641 (rs2943640)	IRS1	C/T	0.65	0.083	Rung <i>et al.</i> , 2009 ²⁷
3:12393125	rs1801282	PPARG	C/G	0.88	0.138	Altshuler <i>et al.</i> , 2000 ²⁸
3:23336450	rs7612463	UBE2E2	C/A	0.89	0.102	Yamauchi <i>et al.</i> , 2010 ²⁹
3:64711904	rs4607103 (rs6795735)	ADAMTS9	C/T	0.76	0.092	Zeggini <i>et al.</i> , 2008 ²⁵
3:123065778	rs11708067 (rs2877716)	ADCY5	A/G	0.75	0.097	Dupuis <i>et al.</i> , 2010 ⁹
4:6292915	rs10010131	WFS1	G/A	0.60	0.104	Sandhu <i>et al.</i> , 2007 ³⁰
5:76424949	rs4457053	ZBED3	G/A	0.32	0.150	Voight <i>et al.</i> , 2010 ²⁶
6:20661250	rs7754840 (rs9368222)	CDKAL1	C/G	0.31	0.170	Zeggini <i>et al.</i> , 2007 ³¹
7:28189411	rs1635852	JAZF1	T/C	0.49	0.120	Zeggini <i>et al.</i> , 2008 ²⁵
7:44235668	rs4607517 (rs1799884)	GCK	A/G	0.18	0.029	Dupuis <i>et al.</i> , 2010 ⁹
7:130466854	rs972283 (rs4731702)	KLF14	G/A	0.51	0.099	Kong <i>et al.</i> , 2009 ³²
8:95937502	rs7845219	TP53INP1	T/C	0.50	0.093	Voight <i>et al.</i> , 2010 ⁴
8:118184783	rs13266634	SLC30A8	C/T	0.69	0.139	Sladek <i>et al.</i> , 2007 ³³
9:22133284	rs10965250	CDKN2A/B	G/A	0.83	0.181	Zeggini <i>et al.</i> , 2007 ³¹
9:81952128	rs13292136	CHCHD9	C/T	0.93	0.182	Voight <i>et al.</i> , 2010 ²⁶
10:12328010	rs12779790 (rs11257655)	CDC123/CAMK1D	G/A	0.18	0.088	Zeggini <i>et al.</i> , 2008 ²⁵
10:94465559	rs5015480	HHEX/IDE	C/T	0.59	0.166	Zeggini <i>et al.</i> , 2007 ³¹
10:114758349	rs7903146	TCF7L2	T/C	0.29	0.335	Grant <i>et al.</i> , 2006 ³⁴
11:1696849	rs2334499	HCCA2/DUSP8	T/C	0.42	0.080	Kong <i>et al.</i> , 2009 ³²
11:2691471	rs231362	KCNQ1	G/A	0.52	0.104	Kong <i>et al.</i> , 2009 ³²
11:2847069	rs163184	KCNQ1	G/T	0.48	0.083	Yasuda <i>et al.</i> , 2008 ³⁵ , Unoki <i>et al.</i> , 2008 ³⁶
11:17408630	rs5215	KCNJ11	C/T	0.36	0.089	Gloyn <i>et al.</i> , 2003 ³⁷
11:72433098	rs1552224	CENTD2	A/C	0.84	0.123	Voight <i>et al.</i> , 2010 ²⁶
11:92673828	rs1387153 (rs10830963)	MTNR1B	T/C	0.29	0.115	Prokopenko <i>et al.</i> , 2009 ³⁸ , Dupuis <i>et al.</i> , 2010 ⁹

Chr:Pos (hg19)	SNP (proxy) ^a	Locus	Alleles (Effect/Other)	Effect Allele Frequency ^b	Beta ^c	Source in which SNP was originally identified
12:66170163	rs2612067	HMGA2	G/T	0.10	0.180	Voight <i>et al.</i> , 2010 ²⁶
12:71613276	rs1353362	TSPAN8/ LGR5	C/T	0.28	0.103	Zeggini <i>et al.</i> , 2008 ²⁵
12:121402932	rs7305618 (rs12427353)	HNF1A	C/T	0.77	0.112	Voight <i>et al.</i> , 2010 ²⁶
13:80717156	rs1359790	SPRY2	G/A	0.71	0.096	Shu <i>et al.</i> , 2010 ³⁹
15:62396389	rs7172432	C2CD4A/B	A/G	0.57	0.068	Yamauchi <i>et al.</i> , 2010 ²⁹
15:77747190	rs7178572	HMG20A	G/A	0.71	0.068	Kooner <i>et al.</i> , 2011 ⁴⁰
15:80432222	rs11634397	ZFAND6	G/A	0.66	0.102	Voight <i>et al.</i> , 2010 ²⁶
17:36098040	rs4430796	HNF1B	G/A	0.48	0.130	Gudmundsson <i>et al.</i> , 2007 ⁴¹
X:152908152	rs2301142	DUSP9	A/G	0.85	0.086	Voight <i>et al.</i> , 2010 ²⁶

SNP, single nucleotide polymorphism.

^aProxy SNPs were genotyped and analysed in the Hyperglycemia and Adverse Pregnancy Outcome Study ($r^2 > 0.7$ in 340,000 British white unrelated samples from UK Biobank²⁴, except for at *ADAMTS9* where $r^2 = 0.45^{24}$).

^bEffect allele frequency was calculated in 340,000 British white unrelated samples from the UK Biobank²⁴.

^cBeta values were aligned to the T2D-risk allele on the + strand (Human Genome Assembly Reference hg19). Beta value = log odds ratio for T2D from genome-wide association study meta-analysis of up to 8130 cases and 38987 controls, published in Voight *et al.* 2010²⁶.

We excluded rs8042680 (*PRC1* locus, Atlantic Diabetes in Pregnancy Study) and rs1470579 (*IGF2BP2* locus, Hyperglycemia and Adverse Pregnancy Outcome Study) from the T2D GS due to deviation from Hardy-Weinberg Equilibrium (Bonferroni-corrected $P < 0.05$). We additionally excluded rs11642841 (*FTO* locus) due to its primary effect on BMI²³.

$$\text{Weighted GS} = \left(\frac{\text{sum (number of alleles for each SNP x Beta)}}{\text{sum of Beta values}} \right) \times \text{total number of SNPs}$$

Figure 2. Formula for generating a weighted genetic score (GS). “Number of alleles” corresponds to either the number of risk alleles (type 2 diabetes single-nucleotide polymorphisms (SNPs)) or the number of glucose-raising alleles (fasting plasma glucose SNPs).

higher overall in DIP. P values were Bonferroni corrected for 16 comparisons.

Statistical software. All statistical analyses were performed using Stata version 14.0 (StataCorp LP, College Station, TX, USA). P -values < 0.05 were considered to indicate evidence of association, unless otherwise stated.

Ethics approval

Ethics approval was obtained from the Northwestern University Office for the Protection of Research Participants for HAPO (Protocol # 0353-001). The HAPO study protocol was approved by the institutional review board at each field center and all participants gave written, informed consent. Ethics approval was obtained from the local Galway University Hospital

Research Ethics Committee for Atlantic DIP (Ref: 54/05) and all participants gave written, informed consent.

Results

Clinical characteristics in women with and without GDM
Clinical characteristics for women with and without GDM are summarised in Table 3 for HAPO and DIP, respectively. Women with a FPG ≥ 5.1 mmol/L (on its own or with either 1-hour or 2-hour hyperglycaemia) had a higher pre-pregnancy BMI than women without GDM in HAPO and DIP (P values < 0.001). Women with both fasting and either 1-hour or 2-hour hyperglycaemia were older compared with controls in HAPO (P value < 0.05 after Bonferroni correction). In HAPO we observed a higher SBP for women diagnosed with GDM by a FPG ≥ 5.1 mmol/L only compared with controls (P value < 0.001) and they had a

Table 3. Clinical characteristics for participants diagnosed with gestational diabetes (GDM) by the different criteria in the Hyperglycemia and Adverse Pregnancy Outcome Study (A) and the Atlantic Diabetes in Pregnancy Study (B).

(A) HAPO					
Variables	Controls with normal glucose	FPG ≥ 5.1 mmol/L only	1-hr glucose ^a ≥ 10 mmol/L only	2-hr glucose ^a ≥ 8.5 mmol/L only	Both (FPG ≥ 5.1 mmol/L and either 1-hr glucose ^a ≥ 10 mmol/L or 2-hr glucose ^a ≥ 8.5 mmol/L)
Median FPG in mmol/L (IQR)	4.5 (4.3-4.7) n=2,275	5.2 (5.1-5.3) n=164	4.8 (4.6-4.9) n=66	4.5 (4.3-4.7) n=48	5.3 (5.2-5.5) n=75
Median 1-hr glucose in mmol/L (IQR)	7.1 (6.0-8.0) n=2,275	8.4 (7.6-9.2) n=164	10.4 (10.2-11.0) n=66	9.0 (8.6-9.5) n=48	10.6 (10.0-11.2) n=75
Median 2-hr glucose in mmol/L (IQR)	5.8 (5.1-6.5) n=2,275	6.6 (6.0-7.1) n=164	7.4 (6.6-7.9) n=66	8.9 (8.6-9.1) n=48	7.9 (7.1-8.9) n=75
Median maternal age in years (IQR)	31 (26-34) n=2,275	31 (27-35) n=164	31 (27-35) n=66	32 (27-34) n=48	32 (29-36)** n=75
Median pre-pregnancy BMI (IQR)	22.9 (21.0-26.1) n=2,125	27.5 (23.8-33.1)*** n=142	24.4 (21.2-27.9) n=59	23.0 (20.1-25.1) n=45	28.0 (23.8-35.2)*** n=65
Median SBP in mmHg (IQR)	108 (102-114) n=2,275	113 (106-119)*** n=164	110 (103-118) n=66	104 (100-116) n=48	110 (103-118)* n=75
(B) DIP					
Variables	Controls with normal glucose	FPG ≥ 5.1 mmol/L only	1-hr glucose ^a ≥ 10 mmol/L only	2-hr glucose ^a ≥ 8.5 mmol/L only	Both (FPG ≥ 5.1 mmol/L and either 1-hr glucose ^a or 2-hr glucose ^a ≥ 8.5 mmol/L)
Median FPG in mmol/L (IQR)	4.3 (4.1-4.5) n=816	5.3 (5.2-5.5) n=58	4.6 (4.4-4.8) n=88	4.5 (4.2-4.7) n=25	5.5 (5.2-5.9) n=97
Median 1-hr glucose ^a in mmol/L (IQR)	6.6 (5.6-7.7) n=816	8.7 (7.5-9.1) n=58	10.8 (10.2-11.2) n=88	8.6 (8.1-9.1) n=25	11.2 (10.2-12.0) n=97
Median 2-hr glucose ^a in mmol/L (IQR)	5.2 (4.6-6.0) n=816	6.1 (5.5-7.0) n=58	6.9 (5.9-7.8) n=88	8.8 (8.6-9.2) n=25	8.5 (7.5-9.3) n=97
Median maternal age in years (IQR)	32 (29-36) n=521	35 (31-39)* n=35	34 (31-37)* n=69	32 (29-40) n=16	33 (30-36) n=72

(B) DIP					
Variables	Controls with normal glucose	FPG ≥ 5.1 mmol/L only	1-hr glucose ^a ≥ 10 mmol/L only	2-hr glucose ^a ≥ 8.5 mmol/L only	Both (FPG ≥ 5.1 mmol/L and either 1-hr glucose ^a or 2-hr glucose ^a ≥ 8.5 mmol/L)
Median pre-pregnancy BMI (IQR)	25.4 (23.4-28.8) n=454	31.6 (29.0-38.3) ^{***} n=33	29.6 (25.5-35.7) ^{***} n=56	28.5 (25.5-31.1) n=16	33.5 (28.3-37.6) ^{***} n=55
Median SBP in mmHg (IQR)	117 (108-124) n=437	119 (110-130) n=21	120 (113-130) [*] n=38	122 (111-134) n=12	120 (115-134) ^{**} n=41

BMI, body mass index; DIP, Atlantic Diabetes in Pregnancy Study; FPG, fasting plasma glucose; HAPO, Hyperglycemia and Adverse Pregnancy Outcome Study; IQR, interquartile range; SBP, systolic blood pressure.

^aThe 1-hour and 2-hour glucose measures refer to the glucose level measured at 1 and 2 hours, respectively, following a 75 g oral glucose load as part of an oral glucose tolerance test.

^{*}*P* value <0.01 for comparison with controls (>0.05 after Bonferroni correction).

^{**}*P* value <0.01 for comparison with controls (<0.05 after Bonferroni correction).

^{***}*P* value <0.001 for comparison with controls (remained <0.001 after Bonferroni correction).

higher SBP when either their 1-hour or 2-hour glucose was also raised, but the *P* value was >0.05 after Bonferroni correction. In DIP there was a higher SBP for women diagnosed by both fasting and either 1-hour or 2-hour hyperglycaemia criteria compared with controls (*P* value <0.05 after Bonferroni correction).

FPG, 1-hour and 2-hour glucose are associated with FPG and T2D GS in pregnant women with and without GDM

FPG, 1-hour and 2-hour glucose values were associated with the fasting and type 2 diabetes genetic scores in HAPO and DIP Table 4. Adjusting for the different measures of glucose tolerance suggested that these associations were not independent of one another.

Women diagnosed with GDM by fasting glucose criteria have a higher FPG GS

We observed a higher FPG GS in women diagnosed with GDM by fasting hyperglycaemia only and by both fasting and either 1-hour or 2-hour criteria, compared with controls (Figure 3A, all *P* values for comparison with control group <0.05 after Bonferroni correction). There was also evidence that women with a raised 1-hour glucose only had a higher FPG GS in HAPO (*P* value for comparison with controls <0.01 but >0.05 with Bonferroni correction), but this was not as strong in DIP (*P* value =0.05). In contrast, women diagnosed with GDM by 2-hour only criteria did not have a higher FPG GS overall (*P* values for comparison with controls >0.05 in both studies).

Women diagnosed with GDM by fasting, 1-hour or 2-hour criteria have a higher T2D GS than controls

The T2D GS was higher than controls in women with fasting, 1-hour or 2-hour hyperglycaemia in HAPO and DIP Figure 2B: all *P* values for comparison with controls were <0.05 after correction except for the fasting and 1-hour only groups.

Discussion and conclusions

In this study of 3,712 pregnant women of European ancestry, we have confirmed that women diagnosed with GDM according to the WHO 2013 criteria have a raised genetic risk for type 2 diabetes and shown for the first time that this risk was raised across all of the different measures of glucose tolerance. A genetic predisposition to a higher FPG was present for women who met the fasting glucose criteria (and 1-hour glucose criteria in HAPO), but was not present for women who met the 2-hour criteria.

We confirmed that FPG in pregnant women both with and without GDM was positively associated with a FPG GS generated using SNPs identified in a non-pregnant population⁹. The 1-hour and 2-hour glucose values were also correlated with the FPG GS, but this could potentially be explained by their association with FPG, since this association was not as strong once this was taken into account. Thus, the observation that the FPG GS was not higher in women diagnosed with GDM due to a 2-hour glucose ≥ 8.5 mmol/L alone was expected. Maternal FPG was also associated with the T2D GS, which would be expected, as there are loci within the T2D GS which also raise fasting glucose (e.g. *GCK*, *MTNR1B*)⁹. The *ADCY5* locus has also been found to be associated with 2-hour glucose values⁴². Thus, the observation of a higher T2D GS in women meeting the fasting or 2-hour WHO 2013 criteria for GDM is not surprising. A GWAS for 1-hour glucose values was not available at the time of writing, but since we found the T2D GS to be associated with 1-hour glucose values in HAPO, it is likely that this explains the higher T2D GS seen in the women meeting this criterion for diagnosis of GDM, and will contribute to the higher T2D GS seen in women with both a fasting and either 1-hour or 2-hour hyperglycaemia. However, it is important to note that the relationships between the T2D GS and the different glucose categories did not appear to be independent of one another, and again,

Table 4. Associations for fasting plasma glucose (FPG) and type 2 diabetes (T2D) genetic scores (GS) with different measures of glucose tolerance in women with and without diabetes in the Hyperglycemia and Adverse Pregnancy Outcome Study (A)^a and the Atlantic Diabetes in Pregnancy Study (B)^b.

(A) HAPO				
Glucose measure	Beta coefficient per one unit higher FPG GS (95% CI)	Beta coefficient per one unit higher FPG GS, with adjustment for other glucose values (95% CI)	Beta coefficient per one unit higher T2D GS (95% CI)	Beta coefficient per one unit higher T2D GS, with adjustment for other glucose values (95% CI)
Fasting	0.028 mmol/L (0.023-0.032 mmol/L)***	0.022 mmol/L (0.018-0.027 mmol/L)***	0.008 mmol/L (0.004-0.011 mmol/L)***	0.003 mmol/L (-3.8 x 10 ⁻⁴ -0.006 mmol/L)
1-hr ^c	0.060 mmol/L (0.040-0.081 mmol/L)***	0.009 mmol/L (-0.007-0.025 mmol/L)	0.051 mmol/L (0.037-0.066 mmol/L)***	0.019 mmol/L (0.008-0.031 mmol/L)**
2-hr ^c	0.032 mmol/L (0.016-0.048 mmol/L)***	0.0003 mmol/L (-0.013-0.013 mmol/L)	0.034 mmol/L (0.022-0.045 mmol/L)***	0.009 mmol/L (0.00001-0.018 mmol/L)
(B) DIP				
Glucose measure	Beta coefficient per one unit higher FPG GS (95% CI)	Beta coefficient per one unit higher FPG GS, with adjustment for other glucose values (95% CI)	Beta coefficient per one unit higher T2D GS (95% CI)	Beta coefficient per one unit higher T2D GS, with adjustment for other glucose values (95% CI)
Fasting	0.050 mmol/L (0.039-0.061 mmol/L)***	0.030 mmol/L (0.021-0.039 mmol/L)***	0.016 mmol/L (0.008-0.025 mmol/L)**	-0.001 mmol/L (-0.008-0.006 mmol/L)
1-hr ^c	0.136 mmol/L (0.093-0.179 mmol/L)***	0.034 mmol/L (-9.35 x 10 ⁻⁶ -0.067 mmol/L)	0.110 (0.079-0.141 mmol/L)***	0.055 mmol/L (0.030-0.078 mmol/L)***
2-hr ^c	0.071 mmol/L (0.038-0.105 mmol/L)***	-0.015 mmol/L (-0.042-0.011 mmol/L)	0.065 mmol/L (0.041-0.089 mmol/L)***	0.014 mmol/L (-0.005-0.033 mmol/L)

CI, confidence interval; DIP, Atlantic Diabetes in Pregnancy Study; HAPO, Hyperglycemia and Adverse Pregnancy Outcome Study. ^aThese analyses were performed in HAPO as it was a representative sample of pregnant women of European ancestry. ^bAs ATLANTIC-DIP had a case-control design the beta coefficients will not be representative of the general pregnant population but are presented for comparison with HAPO. ^cThe 1-hour and 2-hour glucose measures refer to the glucose level measured at 1 and 2 hours, respectively, following a 75 g oral glucose load as part of an oral glucose tolerance test. ** *P* value <0.001, <0.01 after Bonferroni correction. *** *P* value <0.001, remained <0.001 after Bonferroni correction.

although women meeting the diagnosis for GDM in one category may not meet the thresholds for GDM in other categories, they are likely to have a degree of fasting and postprandial hyperglycaemia which will contribute to their higher genetic risk for type 2 diabetes compared with women without GDM.

One might expect that women with both fasting and postprandial hyperglycaemia would have the highest genetic risk for type 2 diabetes, but we did not observe this for the T2D GS in women with both a FPG ≥5.1 mmol/L and either a 1-hour glucose ≥10 mmol/L or 2-hour glucose ≥8.5 mmol/L. On the whole, the relationship between GDM and a higher T2D GS was clearest for women with a raised 2-hour glucose or a combination of raised fasting and 1-hour or 2-hour glucose, but studies with greater statistical power will be needed to confirm whether genetic risk of T2D is heterogeneous across the different thresholds of glucose tolerance that are part of the WHO 2013 criteria for GDM.

Previous studies investigating the association between genetic risk scores for glycaemic traits and GDM have provided interesting insights into the biology of GDM. For example, in a study including women from HAPO as well as a Canadian cohort-study (Gen3G), a fasting glucose genetic risk score was strongly associated with FPG in pregnant women, explaining a similar variance in FPG to the non-pregnant population¹⁸. Furthermore, genetic risk scores for insulin sensitivity and insulin secretion were associated with these traits in pregnancy, emphasising there to be an important shared genetic component to these both in and outside of pregnancy. Several SNPs at risk loci included in the genetic scores for FPG and type 2 diabetes risk in this study have previously been associated with GDM at genome-wide significance (*CDKALI*, *G6PC2*, *GCKR*, *MTNR1B*^{14,43}) and at lesser-degrees of significance (e.g. *HNF1A*, *TCF7L2*, *HHEX/IDE*, *PPARG*^{15,17,18,43}). These loci have been implicated in diverse physiological processes influencing glucose metabolism, such as beta cell function and insulin secretion, and insulin resistance secondary to lipodystrophy

Figure 3. Plots showing mean fasting plasma glucose (FPG) (A) or type 2 diabetes (T2D) genetic score (GS) in each gestational diabetes (GDM) glucose diagnostic category in the Hyperglycemia and Adverse Pregnancy Outcome Study (HAPO) and Atlantic Diabetes in Pregnancy Study (DIP). The 1-hour and 2-hour glucose groups refer to glucose levels measured at 1 and 2 hours, respectively, following a 75 g oral glucose load as part of an oral glucose tolerance test. The control group include women with a FPG <5.1 mmol/L, 1-hour glucose <10 mmol/L and 2-hour glucose <8.5 mmol/L. The fasting only group includes women with a FPG $\geq$ 5.1 mmol/L, a 1-hour glucose <10 mmol/L and 2-hour glucose <8.5 mmol/L. The 1-hour only group includes women with 1-hour glucose $\geq$ 10 mmol/L, FPG <5.1 mmol/L and 2-hour glucose <8.5 mmol/L. The 2-hour only group includes women with a 2-hour glucose $\geq$ 8.5 mmol/L, FPG <5.1 mmol/L and 1-hour glucose <10 mmol/L. The remaining group includes women with both a FPG $\geq$ 5.1 mmol/L and either a 1-hour glucose $\geq$ 10 mmol/L or 2-hour glucose $\geq$ 8.5 mmol/L, or both. Error bars show 95% confidence intervals. **P* value for comparison between cases and controls <0.05 ***P* value for comparison between cases and controls <0.01. ****P* value for comparison between cases and controls <0.001. All *P* values survived Bonferroni correction at $\alpha=0.05$ except for the FPG GS in women with 1-hour hyperglycaemia in HAPO and the T2D GS in women with isolated fasting or 1-hour hyperglycaemia in HAPO and DIP.

and disrupted liver lipid metabolism^{44,45}. Along with previous studies showing associations between GDM and genetic risk scores including SNPs at risk loci associated with type 2 diabetes^{15,18}, our study supports the growing evidence that genetic determinants of glycaemic traits influence both of these phenotypes.

Although genetic predisposition will contribute to the underlying pathophysiology of GDM, it explains only part of GDM risk. So far, models including genetic risk scores for glycaemic traits have shown limited predictive ability^{18,46}, suggesting they may not be sufficiently accurate to be used on their own in determining who should be screened for GDM. Therefore, it is still important to consider other well established risk factors, such as parity, maternal age, BMI, ethnicity and socioeconomic background in stratifying risk of GDM⁵.

This work specifically examining the genetic risk of type 2 diabetes in women diagnosed with GDM according to different

measures of glucose tolerance supports the results from the recent HAPO Follow-Up Study⁴⁷, which showed that women diagnosed with GDM post-hoc according to WHO 2013 criteria had a higher risk for type 2 diabetes 10 to 14 years after pregnancy. We observed the highest BMIs in women diagnosed with GDM by fasting hyperglycaemia only or both criteria, which is consistent with previous research showing that women diagnosed with GDM by the WHO 2013 criteria were more overweight than those diagnosed by WHO 1996 criteria^{7,48}. However, the associations seen for GDM with FPG GS and T2D GS are not driven by BMI (the genetic variants included within the scores do not primarily affect FPG and T2D risk because of an effect on BMI), suggesting that women with fasting hyperglycaemia in pregnancy are likely to have both BMI-related metabolic factors and a genetic predisposition contributing to type 2 diabetes risk. Furthermore, women with an isolated 2-hour hyperglycaemia did not have a significantly higher BMI than controls, which could suggest a more important role for genetic predisposition in this group of women. However, non-genetic

environmental factors related to development of type 2 diabetes such as diet, exercise and socioeconomic deprivation remain a key consideration, as genetics will explain only a portion of risk for type 2 diabetes in women with a history of GDM. For example, a recent study of 2,434 women of white ethnicity found that ~26% women with a history of GDM and a type 2 diabetes genetic risk score in the highest quartile had developed diabetes at follow-up compared with ~23% of women in the lowest genetic risk score quartile¹⁶.

In the longer-term, although using the lower FPG threshold from the WHO 2013 criteria for identifying GDM will result in more cases diagnosed, these women will be an important target for long-term follow-up. It is not known whether lifestyle interventions such as guided diet and exercise programmes could modify risk of progressing to type 2 diabetes in women with a history of GDM and a high genetic risk. A study of 1,744 white women suggested that risk of developing type 2 diabetes after a pregnancy affected by GDM was greatest in women with a high genetic risk score and poor diet¹⁶. On the other hand, while the Diabetes Prevention Program (DPP)⁴⁹ trial found that lifestyle intervention or metformin treatment reduced risk of progression to type 2 diabetes in women with impaired glucose tolerance and a history of GDM (according to relevant criteria at time of diagnosis), a genetic risk score for type 2 diabetes did not influence treatment response⁵⁰. Neither of these studies included women specifically diagnosed by WHO 2013 criteria, but it is clear from this work and that of the HAPO Follow-Up Study that these women would benefit from monitoring after pregnancy and should be considered for targeted lifestyle interventions in public health policies focussing on prevention of type 2 diabetes in adults.

There are limitations of this study that are important to consider. The small number of cases of GDM included has been mentioned and could explain why there were not clear differences in T2D GS seen between the different diagnostic categories. We also studied women from two different studies, where there were notable differences in clinical characteristics, even for women without GDM. Additionally, the FPG and T2D GS were consistently higher in DIP than in HAPO. This is likely to reflect differences in SNPs used to generate the genetic scores and possibly a slightly higher genetic disposition to a raised FPG and type 2 diabetes in DIP. However, there were remarkably similar patterns for the genetic score associations amongst the different diagnostic groups in both studies. The results of these analyses are therefore likely to be applicable to women of European ancestry, but further larger-scale studies, including analysis of women with diverse ancestry, will be needed to confirm the associations identified in this study.

In conclusion, women diagnosed with GDM according to the newest WHO 2013 criteria, regardless of how the diagnosis is met, have a higher genetic risk for type 2 diabetes compared

with women without GDM. Overall, the criteria identify an important group of women at risk for adverse pregnancy outcomes as well as a higher risk for developing future type 2 diabetes⁸, which can partly be explained by genetic predisposition. In addition, this study has added to the literature confirming genetic predisposition to type 2 diabetes in women with GDM and supports the call for considering GDM as a key area of investigation in the field of genetics-led precision medicine.

Data availability

Underlying data

Data is not freely available due to it consisting of potentially identifiable information, and as such is held securely to protect the interests of research participants in line with the guidance from the relevant ethics committees. However, the ethics committees will allow data analysed and generated in this study to be available to researchers through open collaboration. For access to the data used in this study please contact Dr Rachel Freathy (r.freathy@exeter.ac.uk) and Professor William Lowe Jr (wlowe@northwestern.edu) in relation to HAPO and Dr Rachel Freathy and Professor Fidelma Dunne (fidelma.dunne@nuigalway.ie) in relation to Atlantic DIP. Requests will be reviewed as soon as possible on receipt and will be facilitated with an agreement to ensure that data is transferred and held securely and results of new analyses shared with the relevant study investigators. The websites describing the studies and other data available are https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000096.v4.p1 for HAPO and <http://atlanticdipireland.com/> for Atlantic DIP.

Acknowledgements

We acknowledge the work of the HAPO and DIP original investigators, whose names can be viewed in their original publications. We acknowledge the role of all professionals and families who contributed to HAPO and DIP. We acknowledge the use of the University of Exeter High-Performance Computing (HPC) facility in carrying out this work. Part of this study has been conducted using the UK Biobank Resource under Application 7036.

Prior publication

Parts of this work were presented at the European Association for the Study of Diabetes Annual Meeting, Stockholm, Sweden, 14–18 September 2015, the Royal College of Obstetricians and Gynaecologists Annual Academic Meeting, 8–9 February 2018, the East of England Deanery Registrar Prize Meeting, 15 June 2018 and the European Association for the Study of Diabetes Diabetic Pregnancy Study Group Annual Meeting, Graz, Austria, 5–8 September 2019. A previous version of the manuscript was posted as a preprint on bioRxiv, 22 June 2020 (doi: <https://doi.org/10.1101/671057>).

References

1. O'Sullivan JB: **Criteria for the oral glucose tolerance test in pregnancy.** *Diabetes.* 1964; **13**: 278–285.
[PubMed Abstract](#)
2. World Health Organization: **Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy.** 2013; (accessed 11 Aug 2018).
[Reference Source](#)
3. Sermer M, Naylor CD, Gare DJ, *et al.*: **Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto tri-hospital gestational diabetes project.** *Am J Obstet Gynecol.* 1995; **173**(1): 146–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. World Health Organization, International Diabetes Federation: **Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation.** 2006; (accessed 11 Aug 2018).
[Reference Source](#)
5. The HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, *et al.*: **Hyperglycemia and Adverse Pregnancy Outcomes.** *N Engl J Med.* 2008; **358**(19): 1991–2002.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, *et al.*: **International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy.** *Diabetes Care.* 2010; **33**(3): 676–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. O'Sullivan EP, Avalos G, O'Reilly M, *et al.*: **Atlantic Diabetes in Pregnancy (DIP): the prevalence and outcomes of gestational diabetes mellitus using new diagnostic criteria.** *Diabetologia.* 2011; **54**(7): 1670–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Lowe WL, Scholtens DM, Lowe LP, *et al.*: **Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity.** *JAMA.* 2018; **320**(10): 1005–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Dupuis J, Langenberg C, Prokopenko I, *et al.*: **New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.** *Nat Genet.* 2010; **42**(2): 105–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Mahajan A, Taliun D, Thurner M, *et al.*: **Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps.** *Nat Genet.* 2018; **50**(11): 1505–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Wu L, Cui L, Tam WH, *et al.*: **Genetic variants associated with gestational diabetes mellitus: a meta-analysis and subgroup analysis.** *Sci Rep.* 2016; **6**: 30539.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Ding M, Chavarro J, Olsen S, *et al.*: **Genetic variants of gestational diabetes mellitus: a study of 112 SNPs among 8722 women in two independent populations.** *Diabetologia.* 2018; **61**(8): 1758–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Ekelund M, Shaat N, Almgren P, *et al.*: **Genetic prediction of postpartum diabetes in women with gestational diabetes mellitus.** *Diabetes Res Clin Pract.* 2012; **97**(3): 394–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Kwak SH, Kim SH, Cho YM, *et al.*: **A Genome-Wide Association Study of Gestational Diabetes Mellitus in Korean Women.** *Diabetes.* 2012; **61**(2): 531–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Kawai VK, Levinson RT, Adefurin A, *et al.*: **A genetic risk score that includes common type 2 diabetes risk variants is associated with gestational diabetes.** *Clin Endocrinol (Oxf).* 2017; **87**(2): 149–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Li M, Rahman ML, Wu J, *et al.*: **Genetic factors and risk of type 2 diabetes among women with a history of gestational diabetes: findings from two independent populations.** *BMJ Open Diabetes Res Care.* 2020; **8**(1): e000850.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Freathy RM, Hayes MG, Urbanek M, *et al.*: **Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: common genetic variants in GCK and TCF7L2 are associated with fasting and postchallenge glucose levels in pregnancy and with the new consensus definition of gestational diabetes mellitus from the I.** *Diabetes.* 2010; **59**(10): 2682–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Powe CE, Nodzenski M, Talbot O, *et al.*: **Genetic Determinants of Glycemic Traits and the Risk of Gestational Diabetes Mellitus.** *Diabetes.* 2018; **67**(12): 2703–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Scott RA, Lagou V, Welch RP, *et al.*: **Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways.** *Nat Genet.* 2012; **44**(9): 991–1005.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Owens LA, O'Sullivan EP, Kirwan B, *et al.*: **ATLANTIC DIP: The Impact of Obesity on Pregnancy Outcome in Glucose-Tolerant Women.** *Diabetes Care.* 2010; **33**(3): 577–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. HAPO Study Cooperative Research Group: **The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study.** *Int J Gynaecol Obstet.* 2002; **78**(1): 69–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. HAPO Study Cooperative Research Group, Nesbitt GS, Smye M, *et al.*: **Integration of local and central laboratory functions in a worldwide multicentre study: Experience from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study.** *Clin Trials.* 2006; **3**(4): 397–407.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Zhang G, Karns R, Narancic NS, *et al.*: **Common SNPs in FTO gene are associated with obesity related anthropometric traits in an island population from the eastern Adriatic coast of Croatia.** *PLoS One.* 2010; **5**(4): e10375.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Bycroft C, Freeman C, Petkova D, *et al.*: **The UK Biobank resource with deep phenotyping and genomic data.** *Nature.* 2018; **562**(7726): 203–209.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Zeggini E, Scott LJ, Saxena R, *et al.*: **Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes.** *Nat Genet.* 2008; **40**(5): 638–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Voight BF, Scott LJ, Steinthorsdottir V, *et al.*: **Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis.** *Nat Genet.* 2010; **42**(7): 579–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Rung J, Cauchi S, Albrechtsen A, *et al.*: **Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia.** *Nat Genet.* 2009; **41**(10): 1110–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Altshuler D, Hirschhorn JN, Klannemark M, *et al.*: **The common PPARG gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.** *Nat Genet.* 2000; **26**(1): 76–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Yamauchi T, Hara K, Maeda S, *et al.*: **A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B.** *Nat Genet.* 2010; **42**(10): 864–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Sandhu MS, Weedon MN, Fawcett KA, *et al.*: **Common variants in WFS1 confer risk of type 2 diabetes.** *Nat Genet.* 2007; **39**(8): 951–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Zeggini E, Weedon MN, Lindgren CM, *et al.*: **Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes.** *Science.* 2007; **316**(5829): 1336–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Kong A, Steinthorsdottir V, Masson G, *et al.*: **Parental origin of sequence variants associated with complex diseases.** *Nature.* 2009; **462**(7275): 868–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Sladek R, Rocheleau G, Rung J, *et al.*: **A genome-wide association study identifies novel risk loci for type 2 diabetes.** *Nature.* 2007; **445**(7130): 881–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Grant SFA, Thorleifsson G, Reynisdottir I, *et al.*: **Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes.** *Nat Genet.* 2006; **38**(3): 320–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Yasuda K, Miyake K, Horikawa Y, *et al.*: **Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus.** *Nat Genet.* 2008; **40**(9): 1092–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Unoki H, Takahashi A, Kawaguchi T, *et al.*: **SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations.** *Nat Genet.* 2008; **40**(9): 1098–102.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Gloyn AL, Weedon MN, Owen KR, *et al.*: **Large-scale association studies of variants in genes encoding the pancreatic beta-cell K_{ATP} channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes.** *Diabetes.* 2003; **52**(2): 568–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Prokopenko I, Langenberg C, Florez JC, *et al.*: **Variants in MTNR1B influence fasting glucose levels.** *Nat Genet.* 2009; **41**(1): 77–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Shu XO, Long J, Cai Q, *et al.*: **Identification of New Genetic Risk Variants for Type 2 Diabetes.** *PLoS Genet.* 2010; **6**(9): e1001127.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Kooner JS, Saleheen D, Sim X, *et al.*: **Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci.** *Nat Genet.* 2011; **43**(10): 984–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Gudmundsson J, Sulem P, Steinthorsdottir V, *et al.*: **Two variants on**

- chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.** *Nat Genet.* 2007; **39**(8): 977–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Saxena R, Hivert MF, Langenberg C, *et al.*: **Genetic variation in *GIPR* influences the glucose and insulin responses to an oral glucose challenge.** *Nat Genet.* 2010; **42**(2): 142–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Hayes MG, Urbanek M, Hivert MF, *et al.*: **Identification of *HKDC1* and *BACE2* as genes influencing glycemic traits in pregnancy through genome-wide association studies.** *Diabetes.* 2013; **62**(9): 3282–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 44. Udler MS, Kim J, von Grotthuss M, *et al.*: **Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis.** *PLoS Med.* 2018; **15**(9): e1002654.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Mahajan A, Wessel J, Willems SA, *et al.*: **Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes.** *Nat Genet.* 2018; **50**(4): 559–571.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Lamri A, Mao S, Desai D: **Fine-tuning of Genome-Wide Polygenic Risk Scores and Prediction of Gestational Diabetes in South Asian Women.** *Sci Rep.* 2020; **10**(1): 8941.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Lowe WL, Scholtens DM, Lowe LP, *et al.*: **Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity.** *JAMA.* 2018; **320**(10): 1005–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Harreiter J, Simmons D, Desoye G, *et al.*: **IADPSG and WHO 2013 Gestational Diabetes Mellitus Criteria Identify Obese Women With Marked Insulin Resistance in Early Pregnancy.** *Diabetes Care.* 2016; **39**(7): e90–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Ratner RE, Christophi CA, Metzger BE, *et al.*: **Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.** *J Clin Endocrinol Metab.* 2008; **93**(12): 4774–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Sullivan SD, Jablonski KA, Florez JC, *et al.*: **Genetic Risk of Progression to Type 2 Diabetes and Response to Intensive Lifestyle or Metformin in Prediabetic Women With and Without a History of Gestational Diabetes Mellitus.** *Diabetes Care.* 2014; **37**(4): 909–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status: ? ? ?

Version 2

Reviewer Report 08 February 2021

<https://doi.org/10.21956/wellcomeopenres.18020.r41368>

© 2021 Lamri A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Amel Lamri

Department of Medicine, McMaster University, Hamilton, ON, Canada

Hughes et al. derived a fasting plasma glucose (FPG) as well as a type 2 diabetes (T2D) genetic risk scores (GS) in participants from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) and Atlantic Diabetes in Pregnancy (DIP) studies. Pregnant women were assigned to gestational diabetes (GDM) cases or control groups based on their 75g oral glucose tolerance test results using WHO's 2013 criteria. Four different subgroups of cases were devised depending on whether participants exceeded the diagnosis threshold for fasting, 1h-, 2h-glucose measures, or a combination of these. The authors show that FPG GS was lower in GDM controls compared to GDM cases. This association was the strongest when comparing women with a FPG ≥ 5.1 mmol/L only (1-hour glucose < 10 mmol/L and 2-hour glucose < 8.5 mmol/L) vs. controls. T2D GS was also lower in GDM controls compared to cases.

I concur with all the comments from my fellow Reviewers (1 and 2) on this 2nd version of the manuscript.

In addition, I have the following comments/suggestions:

- Tables 1 and 2: Please specify the effect/other allele, effect allele frequency, and beta of the proxy SNPs.
- Table 3: describe the mean and SD of the two GSs in controls as well as in each case group.
- All non-significant results in relation to GS and GDM associations (results shown in Figure 3): There seems to be a big issue with the small samples size in each case group and hence, large SEs. Non-significant results (or results that do not pass multiple testing) are likely due to a lack of statistical power. Similarly, I do not agree with statement (P9 - discussion): "the observation that the FPG GS was not higher in women diagnosed with GDM due to a 2-hour glucose ≥ 8.5 mmol/L alone was expected". The authors could (and should) meta-analyze results from HAPO and DIP to increase their power. Given the differences between the two studies, adjustments for age and BMI should be considered to reduce between study heterogeneity.

Other Minor Modifications:

- There is no mention in the methods about how LD was estimated in UK Biobank (data version, samples selection, software)
- Table 4: please remove all the mmol/L within the table to facilitate reading, (units can be mentioned in the table's headers or in the legend).
- Page 9: under "Women diagnosed with GDM by fasting, 1-hour or 2-hour criteria have a higher T2D GS than controls", please refer to Figure 3B instead of Figure 2B.
- The fact that all weights of T2D GS SNPs were derived from Voigt et al 2010, and that all weights for all FPG GS SNPs were derived from Dupuis et al. 2010 should be mentioned in the methods section under "Generating a genetic score for FPG and type 2 diabetes" (in addition to legends of table 1 and 2) to avoid any confusion with the last column of Table 2.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Genetics and genomics of complex cardio-metabolic traits

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 08 Mar 2021

Alice Hughes

We would like to thank reviewer 3 for their detailed comments on version 2 of the manuscript. We have addressed their points in turn below:

1. Tables 1 and 2: Please specify the effect/other allele, effect allele frequency, and beta of the proxy SNPs.

We have provided the effect/other alleles, EAF and beta for the proxy SNPs in the Tables 1 and 2 as requested. We used the same beta value for proxy SNPs and have clarified this in the table footnote. Thank you for alerting us to this.

2. Table 3: describe the mean and SD of the two GSs in controls as well as in each case group.

We have provided the mean and SD of the GSs to Table 3 as requested.

3. All non-significant results in relation to GS and GDM associations (results shown in Figure 3): There seems to be a big issue with the small samples size in each case group and hence, large SEs. Non-significant results (or results that do not pass multiple testing) are likely due to a lack of statistical power. Similarly, I do not agree with statement (P9 - discussion):" the observation that the FPG GS was not higher in women diagnosed with GDM due to a 2-hour glucose ≥ 8.5 mmol/L alone was expected". The authors could (and should) meta-analyze results from HAPO and DIP to increase their power. Given the differences between the two studies, adjustments for age and BMI should be considered to reduce between study heterogeneity.

We agree with the reviewer's comment that the wide confidence intervals and non-significant P values after adjustment for multiple testing is likely due to the small sample sizes and resulting low power. We mentioned the small sample size could lead to less distinct associations between the diagnostic categories in the eighth paragraph of the discussion, but have clarified this to include the fact that this could be related to low power. It now reads: "The small number of cases of GDM included has been mentioned and this could have meant that the study was underpowered to show clear differences in T2D GS between the different diagnostic categories".

Regarding the comment on it being expected that there was not a higher FPG GS in individuals with a raised 2-hour glucose, we agree that in the context of a small study, that this might represent the sample size, rather than a considerably lower genetic predisposition to raised fasting glucose. However, we do think it remains the case that women who meet the criteria for GDM because of a raised 2-hour glucose alone but not a raised fasting glucose will likely have a lower FPG GS than women who meet the criteria because of fasting hyperglycaemia, and that was supported by the results in both cohorts. We have changed the wording of this to reflect these points to: "Thus, the observation that the FPG GS was not higher in women diagnosed with GDM due to a 2-hour glucose ≥ 8.5 mmol/L alone was likely because these women did not have fasting hyperglycemia. However, larger sample sizes would be needed to confidently rule out differences in FPG GS between these groups."

Meta-analysis of the results from both cohorts would improve power, and we did intend to do this when we set-out to complete this work. However, due to the different structures of the separate studies (in HAPO a random subset were genotyped, whilst DIP genotyped three women without GDM for every one woman diagnosed with GDM using the clinical criteria at the time of recruitment), different SNPs (proxies were used in the HAPO GS, please see the Methods section for more details), higher GSs in the DIP cohort and different

proportions of women in the different diagnostic categories, we felt that meta-analysis would not be combining like-for-like. We do think that the similar patterns of association support the findings in both studies, but for the reasons mentioned we took the decision not to meta-analyse. These reasons are shown in paragraph 8 of the discussion, but we agree that a comment making it clear that these were reasons precluding meta-analysis should be added and have done so in paragraph 8 of the discussion: "Meta-analysis would have improved power, but was not appropriate due to these differing aspects of each study".

4. There is no mention in the methods about how LD was estimated in UK Biobank (data version, samples selection, software)

Thank you for pointing this important detail about LD estimates out. We have added to the footnotes of Tables 1 and 2 how LD was calculated.

5. Table 4: please remove all the mmol/L within the table to facilitate reading, (units can be mentioned in the table's headers or in the legend).

We have edited Table 4 to remove the multiple instances of mmol/L to help make it more readable.

6. Page 9: under "Women diagnosed with GDM by fasting, 1-hour or 2-hour criteria have a higher T2D GS than controls", please refer to Figure 3B instead of Figure 2B.

Thank you for pointing out this typo, we have corrected it accordingly.

7. The fact that all weights of T2D GS SNPs were derived from Voigt et al 2010, and that all weights for all FPG GS SNPs were derived from Dupuis et al. 2010 should be mentioned in the methods section under "Generating a genetic score for FPG and type 2 diabetes" (in addition to legends of table 1 and 2) to avoid any confusion with the last column of Table 2.

Thank you for pointing this out. We have added a sentence to that effect in the Methods section (please see response 2 to reviewer 1 for more details).

Competing Interests: We are the authors of the article. We have no other competing interests to disclose.

Reviewer Report 07 December 2020

<https://doi.org/10.21956/wellcomeopenres.18020.r39654>

© 2020 Shaat N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nael Shaat

¹ Department of Endocrinology, Skåne University Hospital, Malmö, Sweden

² Department of Clinical Sciences, Genomics, Diabetes and Endocrinology, Lund University, Malmö, Sweden

Authors have investigated whether the fasting, 1-hour and 2-hour glucose thresholds from the WHO 2013 criteria for GDM have different genetic susceptibility to raised fasting glucose and type 2 diabetes in women from 2 cohorts, the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) and Atlantic Diabetes in Pregnancy (DIP) studies. For this purpose, they used genetic scores for fasting plasma glucose (FPG GS) and type 2 diabetes (T2D GS). The main findings were that the mean FPG GS and mean T2D GS were higher in women with only a FPG ≥ 5.1 mmol/L (or combined with 1- or 2-h glucose) than in controls. In addition, mean T2D GS in women with a raised FPG alone or with either a raised 1-hour or 2-hour glucose was higher than controls. Authors concluded that women with a history of GDM have a higher risk of type 2 diabetes in later-life and the risk differs according to how the diagnosis of GDM is met.

The paper is interesting. Many questions have already been raised by the other reviewer.

I have 2 comments:

1. The authors should mention the statistical power of the study.
2. I agree with the other reviewer that the analyses should be adjusted for BMI even if the authors have excluded SNPs associated with BMI.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Gestational diabetes.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 08 Mar 2021

Alice Hughes

We would like to thank reviewer 2 for their time in helping to improve the manuscript. We have addressed their two points as follows:

1. The authors should mention the statistical power of the study. The expected size of any genetic score difference between the case and control groups was unknown. However, as an indicative power calculation, our sample of N=2,628 HAPO and N=1,084 DIP participants both provided 100% power to detect associations between fasting glucose levels and the fasting glucose GS at $\alpha=0.002$, assuming the GS explains 6% variance in glucose levels, which was estimated in 849 pregnant individuals without diabetes in an external study (Exeter Family Study of Childhood Health (EFSOCH)). We have added this information to the Methods under the subheading "Analysis of associations between FPG GS or T2D GS with glucose levels and GDM." of the "Statistical analyses" section.

2. I agree with the other reviewer that the analyses should be adjusted for BMI even if the authors have excluded SNPs associated with BMI.

We have addressed adjustments for BMI in response to point number 3 of reviewer 1.

Competing Interests: We are the authors of the article. We have no other competing interests to disclose.

Reviewer Report 12 November 2020

<https://doi.org/10.21956/wellcomeopenres.18020.r41234>

© 2020 Kawai V. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vivian K. Kawai

Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA

I have the following comments for the reviewed manuscript:

1. SNPs for FPG risk score in Table 1 comes from Dupuis et al., 2010 study, which is OK since this is probably the largest GWAS for fasting glucose in individuals of European ancestry.
2. However, table 2 shows that selected T2D variants came from different studies and populations. Effect estimates depend largely on the sample size and the allele frequency of the variant in a population, as well as the impact of a variant in specific population ancestries. Thus, the authors need to comment how this approach could have affect their results and why they select this approach over using a non-weighted GRS or using only estimates from the largest study in European ancestry regardless of the p-value reported.

An alternative approach is to use one of the cohort to define the estimates for each variant and then use this estimates in the second cohort to calculate the GRS.

3. The authors argue that BMI is unlikely to explain the association observed between GDM and the risk scores because the variants included into the GRS has no effect on BMI. They also say that adjusting for BMI has the potential to bias estimates since patients with higher risk scores are likely to developed GDM at lower BMI, which is true. However, confounding is a major problem in genetic studies and with the data shown, we cannot rule out that BMI is a major driven of the results, which undermines the study. A sensitivity analysis including pre-pregnancy BMI and maternal age is recommended as well as a discussion of how including BMI in the analysis may affect the estimates.
4. Although this was not the scope of the study, the authors should add a short comment why the performance of these GRS for T2D in the HAPO and DIP cohort was not studied, particularly when they mentioned that women in HAPO cohort with GDM had higher risk for T2D 10 to14 years after pregnancy. This is a question that probably every reader would have.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: risk assessment

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 08 Mar 2021

Alice Hughes

We would like to thank reviewer 1 for reviewing the second version of the manuscript, having already commented on the first version. We have made changes to improve the manuscript based on the new comments and have addressed them below:

1. SNPs for FPG risk score in Table 1 comes from Dupuis et al., 2010 study, which is OK since this is probably the largest GWAS for fasting glucose in individuals of European ancestry. Yes, the SNPs and effect size estimates part of the FPG genetic score come from one study (Dupuis et al.)

2. However, table 2 shows that selected T2D variants came from different studies and populations. Effect estimates depend largely on the sample size and the allele frequency of the variant in a population, as well as the impact of a variant in specific population ancestries. Thus, the authors need to comment how this approach could have affect their results and why they select this approach over using a non-weighted GRS or using only estimates from the largest study in European ancestry regardless of the p-value reported. An alternative approach is to use one of the cohort to define the estimates for each variant and then use this estimates in the second cohort to calculate the GRS.

We did not use effect size estimates from different studies. The effect sizes were all derived from one GWAS (Voight et al., which was the biggest and most recently available study at the time of genotyping). This is shown by the superscript "c" in the "Beta" column. The studies in the last column refer to where the SNP was originally identified. Reviewer 3 picked up on this being unclear and we have taken their advice to include a sentence under "Generating a genetic score for FPG and type 2 diabetes" in the Methods section that reads: "All weights for the FPG GS and T2D GS were taken from Dupuis et al.⁹ and Voight et al.²⁶, respectively.

3. The authors argue that BMI is unlikely to explain the association observed between GDM and the risk scores because the variants included into the GRS has no effect on BMI. They also say that adjusting for BMI has the potential to bias estimates since patients with higher risk scores are likely to developed GDM at lower BMI, which is true. However, confounding is a major problem in genetic studies and with the data shown, we cannot rule out that BMI is a major driven of the results, which undermines the study. A sensitivity analysis including pre-pregnancy BMI and maternal age is recommended as well as a discussion of how including BMI in the analysis may affect the estimates.

BMI may confound genetic estimates due to collider bias, as we stated in our previous response. We would not expect the relationships between GS and GDM diagnosis to change according to maternal BMI and age as the SNPs are not causally associated with higher BMI or age. The directed acyclic graph (DAG, found in Extended data file: <https://doi.org/10.6084/m9.figshare.14180033>) illustrates this.

However, since all reviewers have requested it, we have performed analyses adjusted for maternal pre-pregnancy BMI and age (where available) and present the adjusted GS means and 95% confidence intervals for each GDM diagnostic criteria and controls in an Extended Data table which can be found at the following link: <https://doi.org/10.6084/m9.figshare.14180033>

The estimates and associations are very similar to those shown in the main manuscript (see Figure 3; to aid comparison we have added a column in the Extended data table with the unadjusted values). Since BMI and maternal age were not available in all participants (93% of HAPO participants and 51% of DIP participants), the sample size for the adjusted analyses was smaller and there was a corresponding attenuation of the strength of associations (as shown by wider confidence intervals). However, as can be seen by comparing the adjusted and non-adjusted GSs, the estimates were within the 95% CI of the non-adjusted associations, indicating that they were consistent between the adjusted and non-adjusted analyses. We would prefer not to include this data in the main manuscript for the reasons discussed above and in our previous response, but we have included the sentences “sensitivity analyses adjusted for maternal BMI and age did not materially alter the GS relationships (Extended data Tables 1A and 1B)” and “As with the FPG GS, sensitivity analyses adjusted for maternal BMI and age did not materially affect the associations seen (Extended data Tables 1A and 1B).” in the “Women diagnosed with GDM by fasting glucose criteria have a higher FPG GS” and “Women diagnosed with GDM by fasting, 1-hour and 2-hour criteria have a higher T2D GS than controls” sections of the results, respectively.

4. Although this was not the scope of the study, the authors should add a short comment why the performance of these GRS for T2D in the HAPO and DIP cohort was not studied, particularly when they mentioned that women in HAPO cohort with GDM had higher risk for T2D 10 to 14 years after pregnancy. This is a question that probably every reader would have.

The individuals genotyped in this study do not completely crossover with individuals included in the HAPO Follow-Up Study and since the follow-up time has been short so far, we are unlikely to have the power to study the performance of the T2D score with incident T2D in this cohort, although this is something that would be valuable to do in the future. We agree that a comment on this would be helpful and have added the following sentence to the discussion at the end of the sixth paragraph “The GSs in this study were not analysed for their association with incident T2D in the HAPO Follow-Up Study, but this would be useful to establish and make direct comparisons with the results of this work in the future”.

Competing Interests: We are the authors of the article. We have no other competing interests to disclose.

Version 1

Reviewer Report 25 September 2020

<https://doi.org/10.21956/wellcomeopenres.17665.r40254>

© 2020 Kawai V. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vivian K. Kawai

¹ Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA

² Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA

The manuscript by Hughes A.E. and collaborators titled: All thresholds of maternal hyperglycaemia for the WHO 2013 criteria for gestational diabetes identify women with a higher genetic risk for type 2 diabetes" test the hypothesis that each diagnosed criteria have different genetic risk using a FPGGS and a T2D GS.

I have the following comments:

1. Please clarify what is the objective of the study and the clinical utility.
2. Previous studies have shown the limited utility GRS for T2 (and likely FPG) in the detection of women at risk for GDM, suggesting that either other genetic factors are the main driver of GDM or environmental exposures. The authors did not provide a convincing explanation in their discussion of the relevance of their findings.
3. Having an increase genetic risk for T2D or fasting hyperglycemia is irrelevant if the authors cannot show what are the clinical implications of this genetic susceptibility. It is known that women with GDM are at higher risk for developing T2D in the future, but the real question is whether a high genetic susceptibility or other clinical factors are the main drivers of this risk in women who already experienced GDM.
4. A major drawback of using GS is that they cannot provide mechanistic insights, so it is unclear how the use of GS for T2D and FPG for GDM can provide any relevant information in GDM.
5. Please provide a more comprehensive explanation for the GS calculation.
6. What is the definition of European ancestry: self-reported white or was based on population stratification analysis.
7. Pre-pregnancy BMI and maternal age are well known risk factors for GDM. I suggest supporting the statement that the association seen between the GS and the different diagnostic criteria are not driven by BMI with data. We cannot assume that variants have the same impact in BMI variability in non-pregnant and pregnant populations.
8. Table 4, please confirm that the outcomes follow normal distribution and provide results for DIP

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

No

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: risk assessment

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 13 Oct 2020

Alice Hughes

We thank the reviewer for their constructive comments on this work. With the help of these comments we have taken the opportunity to improve the manuscript. We have addressed their comments in turn below and updated the manuscript accordingly (Version 2).

1. Please clarify what is the objective of the study and the clinical utility.

Thank you for prompting us to clarify the message of the paper by stating the objective of the study. The objective of the study was to investigate whether there was a difference in genetic risk for fasting hyperglycaemia and type 2 diabetes according to the different diagnostic thresholds of glucose tolerance as part of the WHO 2013 criteria for gestational diabetes (GDM). We originally stated this in the form of a hypothesis to test in the last paragraph of the introduction, but we have updated the introduction to refocus it as an objective of the study instead (paragraph 4 of the "Introduction" section).

In relation to the clinical utility of the study there are several points to consider. The thresholds for fasting, 1-hour and 2-hour glucose in the WHO 2013 criteria were chosen based on their Obstetric risks (i.e. primary caesarean section, large for gestational age baby, HAPO study reference: <https://doi.org/10.1056/NEJMoa0707943>). Although it is well known that women with a history of GDM have a higher risk of type 2 diabetes in later-life, it is not known if this differs according to how the diagnosis of GDM is met, and whether this may partly reflect underlying predisposing genetic factors. As expected, we observed a higher genetic risk for fasting hyperglycaemia in women who had a met the fasting plasma glucose criteria (≥ 5.1 mmol/L). We observed a higher genetic risk for type 2 diabetes across all diagnostic categories. Therefore, these criteria identify an important group of women with a

genetic risk for type 2 diabetes. This is important for the clinical community to be aware of, since there are many different criteria for GDM used across the world which utilise different criteria (for example, in the United Kingdom the fasting glucose cut-off is 5.6 mmol/L and in Denmark a fasting glucose is not included). Our findings support the findings of the HAPO Follow-Up Study, which showed women diagnosed with GDM according to the WHO 2013 criteria had higher rates of disorders of glucose metabolism 10 years later (Reference: <https://doi.org/10.1001/jama.2018.11628>). The genetic risk is of particular interest for women who meet the criteria for GDM due to a high 2-hour glucose, as we did not observe a significantly higher BMI in this group of women. Therefore, if they had not been identified as having GDM, these women may not necessarily be considered a high-risk group who would require monitoring and follow-up (e.g. with an annual HbA1c). We have added to the discussion to emphasise the potential implications for long-term follow-up (paragraph 6, "Discussion and conclusion" section).

Of course, it is not known whether preventative lifestyle interventions could modify this genetic risk; we touch on this in the discussion in relation women with a history of GDM in the Diabetes Prevention Program (DPP) trial (Reference: <https://dx.doi.org/10.2337%2Fdc13-0700>). A recent study suggested that a genetic score for type 2 diabetes was more strongly associated with developing type 2 diabetes in women with a history of GDM and a poor diet (Reference: <https://dx.doi.org/10.1136%2Fbmjdc-2019-000850>). But, they also point out that the relationship between the T2D genetic risk score and incident type 2 diabetes was modest. We have added to this area of the discussion to provide a more balanced discussion on the potential implications of a high genetic risk for type 2 diabetes, emphasising the uncertainty of whether the genetic risk could be of benefit in targeting public health interventions in relation to post-GDM care (paragraphs 6 and 7).

2. Previous studies have shown the limited utility GRS for T2 (and likely FPG) in the detection of women at risk for GDM, suggesting that either other genetic factors are the main driver of GDM or environmental exposures. The authors did not provide a convincing explanation in their discussion of the relevance of their findings.

We agree that the genetic risk for fasting hyperglycaemia and type 2 diabetes will only explain a portion of risk for GDM. The genetic risk will not explain risks associated with BMI, maternal age, parity and socioeconomic deprivation. In addition, these genetic scores will not explain the higher risks for GDM seen in women of African and South Asian heritage, for example. Whilst this study did not aim to assess the power of the genetic scores to diagnose or predict GDM, we have added to the discussion taking into account these considerations and referencing studies that have focussed on this as a new paragraph in the discussion (paragraph 5 of "Discussion and conclusion" section).

3. Having an increase genetic risk for T2D or fasting hyperglycemia is irrelevant if the authors cannot show what are the clinical implications of this genetic susceptibility. It is known that women with GDM are at higher risk for developing T2D in the future, but the real question is whether a high genetic susceptibility or other clinical factors are the main drivers of this risk in women who already experienced GDM.

We have partially responded to the clinical implications in response to comment 1 and point to the updated version of the discussion. Similar to comment number 2, we agree that

genetic risk is likely to explain only a portion of risk for type 2 diabetes and we have added to the discussion to emphasise the importance of other factors (please see paragraph 6 of the “Discussion and conclusion” section and the response to comment 1 above). However, we also believe that genetic risk for type 2 diabetes and fasting hyperglycaemia are likely to explain part of the relationship between GDM and type 2 diabetes in later-life. We discuss this in more detail in paragraphs 4 and 6 of the “Discussion and conclusion” section.

4. A major drawback of using GS is that they cannot provide mechanistic insights, so it is unclear how the use of GS for T2D and FPG for GDM can provide any relevant information in GDM.

We believe that genetic scores provide important insights into the biology of GDM. For example, the risk loci included in the scores have been implicated in beta cell function, proinsulin secretion and impaired insulin action secondary to unfavourable metabolic patterns of adiposity and liver lipid metabolism (References: <https://doi.org/10.1371/journal.pmed.1002654> and <https://doi.org/10.1038/s41588-018-0084-1>). The relevance of this to GDM was underlined in a recent paper by Powe et al. (Reference: <https://doi.org/10.2337/db18-0203>), which showed associations between genetic risk scores for fasting glucose, fasting insulin, and insulin secretion and sensitivity with GDM. In particular, they also observed strong associations between a fasting glucose GS and fasting glucose in pregnancy, similar to the associations seen outside of pregnancy, emphasising an important shared genetic predisposition. We did not seek to repeat the biological relevance of these associations demonstrated in this paper in our work, but rather show that there is a higher genetic risk for type 2 diabetes associated with the different measures of glucose tolerance in the WHO 2013 criteria for GDM. However, we agree that a discussion considering the likely underlying biology of genetic scores in relation to type 2 diabetes and GDM will help add to the context of the paper and have included a new paragraph in relation to this in the discussion (paragraph 4).

5. Please provide a more comprehensive explanation for the GS calculation.

We have provided a description of the genetic score (GS) calculation in the Methods section under the heading titled “Generating a genetic score for FPG and type 2 diabetes”. We have also included the formula used in Figure 2. We have added a sentence referring to Tables 1 and 2 which show where the beta (effect size) was obtained for each SNP used in the score to clarify this further.

6. What is the definition of European ancestry: self-reported white or was based on population stratification analysis.

European ancestry was based on self-reported white ethnicity in both HAPO and DIP. We have added this to the Methods section under the heading titled “Study population”.

7. Pre-pregnancy BMI and maternal age are well known risk factors for GDM. I suggest supporting the statement that the association seen between the GS and the different diagnostic criteria are not driven by BMI with data. We cannot assume that variants have the same impact in BMI variability in non-pregnant and pregnant populations.

The SNPs at the risk loci included in the genetic scores influence glycaemic traits independent of BMI. We did not include SNPs which had their main effect on BMI (e.g. *FTO*). As BMI is not on the causal pathway between the genetic score and the outcome (GDM diagnostic criterion) it is not necessary to adjust for it in analyses, hence why it is not included in the data presented in this paper. Adjusting for BMI also has the potential to bias estimates due to collider-stratification bias (Reference: <https://doi.org/10.1093/hmg/ddw433>). For example, we observe a paradoxical negative correlation between the T2D GS and pre-pregnancy BMI in HAPO (Spearman's Rho -0.05, *P* value 0.01). This is not a true association and comes about because individuals with a higher genetic risk score are more likely to develop type 2 diabetes at a lower BMI than individuals with a lower genetic risk score. However, we agree that there are key differences in GDM risk according to BMI, which we have shown in the comparison of BMI between the different diagnostic criteria in Table 3 summarising the clinical characteristics of the participants in the studies. We have expanded on the importance of the role of BMI contributing to risk of type 2 diabetes and GDM in the discussion (see responses to Comments 1 and 3 and paragraphs 5 ad 6 of the "Discussion and conclusions" section).

8. Table 4, please confirm that the outcomes follow normal distribution and provide results for DIP.

Fasting glucose, 1-hour and 2-hour glucose have a positive skew in both HAPO and DIP (hence their presentation of median with IQR in Table 3). A normal distribution of outcomes is not a pre-requisite for linear regression models (Reference: <https://doi.org/10.1017/CBO9780511790942>), so we do not think this is of concern for this analysis, but we are happy to supply additional information if the reviewer would like this. We have now included a second part to the table with the associations in DIP (which had a similar pattern of associations to HAPO), but with a cautionary note (footnote b to Table 4) that the beta coefficients seen in a case-control study design will not be applicable to a general pregnant population due to the relative over-representation of cases of GDM. Now we have included these analyses *P* values for association have been corrected for 24 comparisons and we have updated the Methods section under the heading "Statistical analyses".

Competing Interests: We have no competing interests to declare.